Pluri Inc.
A biotechnology company in Haifa, Israel, that grows human, animal, and plant cells at industrial scale using a three-dimensional cell-expansion platform. Its placenta-derived PLX cell therapies target inflammatory and muscle conditions, while the same technology also feeds cultivated-meat and agricultural projects. Founded from stem-cell patents developed during founder Shai Meretzki's PhD at the Technion, it was long known as Pluristem Therapeutics before shortening its name to Pluri in 2022 — a nod to "pluripotent" cells.
Granted 625.0K
Granted 180.0K
Granted 31.6K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Chutzpah Holdings Ltd +1 co-filer10% owner, Director, 10% owner · 2 transactions | — | 4.78M | 625.0K | — | — |
| Manieu Alexandre WeinsteinDirector, 10% owner · 1 transaction | — | 3.83M | 180.0K | — | — |
| Shorrer DoronDirector · 1 transaction | -58.8% | 45.2K | 31.6K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.